AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00733525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Therapy focusing on skills needed to alter eating patterns
Study NCT00733525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Therapy focusing on skills needed to alter eating patterns
Study NCT00733525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
Study NCT00733525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
Study NCT00733525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help
Description: Manual designed to impart teachings of cognitive behavioral therapy
Study NCT03024216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab1200 mg IV
Description: Subjects in ARM 1 will receive 2 doses of atezolizumab 1200 mg intravenously (week 1 and week 4). If no dose limiting toxicity continue onto maintenance, week 13 and receive atezolizumab 1200 mg intravenously every 3 weeks until toxicities or lack of clinical benefit. Subjects in ARM 2 will receive 2 doses at approximately 3 weeks each of atezolizumab 1200 mg intravenously (weeks 7 and 10). If no dose limiting toxicity, continue to receive atezolizumab 1200 mg intravenously every 3 weeks, starting week 13, until toxicities or lack of clinical benefit.
Study NCT03024216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Description: Subjects in ARM 1 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 6, 8, 10). Subjects in ARM 2 will receive sipuleucel-T administered in 3 doses at approximately 2-week intervals (weeks 1, 3 and 5)
Study NCT02700984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
Study NCT02700984 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract Surgery
Description: Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
Study NCT02700984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract Surgery
Description: Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
Study NCT01105637 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Augmented Exercise Program
Description: 12 week (3 x per week) exercise prescription
Study NCT03494647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cheetah Heel Cup
Description: The Cheetah Heel Cup is composed of a rubber waffle that cups the athlete's heel, secured in place by a neoprene sleeve.
Study NCT03494647 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The X Brace
Description: The X Brace is composed of one thick elastic band that is wrapped around the athlete's arch of the foot. A second band is wrapped around the back of the heel, crossed under the foot, and secured to the thicker band on the bottom of the foot.
Study NCT02475889 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatic RFA
Description: Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
Study NCT02475889 — intervention group
Intervention type: PROCEDURE
Intervention: Primary tumor resection
Description: Primary tumor resection were performed pre- or post-RFA for liver metastases.
Study NCT02295722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: gemcitabine 1.5 g/m2 INFUSED
Study NCT02295722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 200 mg/m2
Study NCT02295722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Day 0 - Stem cell infusion
Study NCT00473876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
Study NCT00473876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo (Capsules)
Description: Similar dosing regime as active comparator
Study NCT01099969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidescope videolaryngoscope
Study NCT01099969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope videolaryngoscope
Study NCT01099969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath videolaryngoscope
Study NCT01099969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath videolaryngoscope
Study NCT01099969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-styletted Endotrol endotracheal tube (ETT)
Study NCT01099969 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular endotracheal tube (ETT) with Gliderite stylet
Study NCT03135366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keheala
Study NCT03135366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
Study NCT04083846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reference drug
Description: D744 Cap. 1 Cap., single oral administration under fed condition
Study NCT04083846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 1
Description: CKD-385 64 mg formulation I Tab. 1 Tab., single oral administration under fed condition
Study NCT01138878 — intervention group
Intervention type: OTHER
Intervention: HIV test (serum or salivary)
Description: An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
Study NCT04083846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug 2
Description: CKD-385 64 mg formulation II Tab. 1 Tab., single oral administration under fed condition
Study NCT02648347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Study NCT02648347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis.
Study NCT01138878 — intervention group
Intervention type: OTHER
Intervention: Semi-structured telephone interview
Description: Telephone interview administered to patients offered an HIV test during the pilot period
Study NCT03653871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performing Arts Instruction
Description: Professionally delivered performing arts curriculum
Study NCT03320551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immersion program
Description: Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
Study NCT00617305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
Study NCT00617305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to match ambrisentan was administered orally once daily.
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-866949
Description: (Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
Study NCT00949767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: (Matching volume) - Oral Solution, Oral, once 14 days
Study NCT01470677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tachosil fibrin patch
Description: A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
Study NCT03409874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Dry needling to the muscle of mastication and temporomandibular joint capsule. 1-2 treatment sessions per week for up to 4 weeks
Study NCT03409874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Description: Spinal manipulation, targeting the upper cervical spine (C1-C2, C2-C3 or OA). 1-2 treatments per week for up to 4 weeks.
Study NCT03409874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interocclusal Appliance
Description: Interocclusal appliance worn every nights for 4 weeks.
Study NCT03409874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAIDs
Description: diclofenac (Voltaren) 3 X 50mg per day for 4 weeks. If the patient's TMJ pain improves, the dosage may be reduced to 2 X 50mg per day.
Study NCT03409874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMJ Mobs
Description: Temporomandibular joint mobilization targeting the temporomandibular joint capsule. 1-2 treatments per week for up to 4 weeks.
Study NCT01455974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L
Description: After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
Study NCT04597476 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fucoidan
Description: Fucoidan refers to a class of fucose-enriched sulfated polysaccharides with an average molecular weight of 20,000 Daltons (Da), which can be found in many varieties of edible brown seaweeds and algae . In cell culture studies and animal studies, fucoidan has been shown to possess a range of biological activities, including anti-cancer, anti-inflammatory, and immunoregulatory effects . A recent in vitro study conducted in head and neck squamous cell carcinoma (HNSCC) cell lines (H103, FaDu, and KB) showed that fucoidan could induce cell cycle arrest and possibly apoptosis in a dose-dependent manner, while also enhancing response to cisplatin treatment . In addition, fucoidan has also been shown to inhibit the proliferation of nasopharyngeal carcinoma cells and MC3 human mucoepidermoid carcinoma (MEC) cells .
Study NCT04597476 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo( Potato starch)
Description: Potato starch 4.4gram
Study NCT02393209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion
Study NCT02393209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-117
Description: TAK-117 Tablets
Study NCT03716479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Fiber
Description: 20 g of acacia gum will be added to orange juice
Study NCT03716479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fiber
Description: 40 g of acacia gum will be added to orange juice
Study NCT03716479 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/Control
Description: No acacia gum will be added to orange juice.
Study NCT01973855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Western Medicine
Description: Physical cooling,Hydrocortisone
Study NCT01973855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM and Western Medicine
Description: Third Infectious diseases soup recipe
Study NCT01973855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM and Western Medicine
Description: Third Infectious diseases soup recipe
Study NCT00152633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Study NCT00152633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Study NCT00152633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Treatment with Losartan
Study NCT00723957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone, 32 mg/m^2
Description: Intravenous (IV) solutions, ixabepilone, 32 mg/m\^2
Study NCT00617305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
Study NCT00617305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
Study NCT00723957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel, 200 mg/m^2
Description: IV solutions, paclitaxel, 200 mg/m\^2
Study NCT00723957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin (area under the concentration curve [AUC] 6)
Description: Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
Study NCT00723957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin (area under the concentration curve [AUC] 6)
Description: Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
Study NCT01007526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCRT followed by VIDL chemotherapy
Description: CCRT followed by VIDL chemotherapy concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
Study NCT00746499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg raltegravir BID x 7 days
Study NCT03543683 — intervention group
Intervention type: DRUG
Intervention: Osimertinib
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
Study NCT03543683 — intervention group
Intervention type: DRUG
Intervention: Aspirin
Description: Aspirin, also known as acetylsalicylic acid (ASA), is a very safe medication used to treat pain, fever, or inflammation.
Study NCT00974220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: single dose, 50 mcg of nebulized fentanyl citrate
Study NCT00974220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline (placebo)
Description: single dose, 0.9% saline solution
Study NCT01136343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifestyle modified project
Description: education, counseling
Study NCT01422005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous Bimanual training
Description: Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.~Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy.
Study NCT01422005 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Occupational Therapy
Description: Conventional Occupational Therapy will be given to patients in the control group.
Study NCT02962843 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IY TCM
Description: The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 \& 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills \& Problem Solving.
Study NCT03720392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMT
Description: FMT is a process utilizing microbial components which are the good, healthy bacteria that would otherwise naturally occur in the body.
Study NCT03720392 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a harmless pill, medicine, or procedure prescribed more for the psychological benefit to the patient than for any physiological effect.
Study NCT03441217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine Butylbromide 20Mg/1mL Injection
Description: Nulliparous women with gestations at term receive 20 mg of Hyoscine butylbromide upon arrival in the Labor and Delivery Unit (4-5 cms).
Study NCT03441217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Nulliparous women with gestations at term receive 20 mg of saline solution upon arrival in the Labor and Delivery Unit (4-5 cms).
Study NCT01910077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrobell capsule 1mg
Description: 1 capsule, oral, over the period I\&II(crossover)
Study NCT01910077 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf capsule 1mg
Description: 1 capsule, oral, over the period I\&II(crossover)
Study NCT01278927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
Study NCT01278927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
Study NCT01278927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Stress Management
Description: Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
Study NCT01278927 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
Study NCT02282787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEXMEDETOMIDINE
Description: Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
Study NCT04537780 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tabled every day
Study NCT04537780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Montelukast 10 mg daily at bed time.
Study NCT03489954 — intervention group
Intervention type: OTHER
Intervention: Evaluation
Description: Deep cervical flexor muscle endurance, neck position sense and body balance will be measured.
Study NCT00821509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand washing
Description: Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home